Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

252 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Noninvasive tests of CYP3A enzymes.
Watkins PB. Watkins PB. Pharmacogenetics. 1994 Aug;4(4):171-84. doi: 10.1097/00008571-199408000-00001. Pharmacogenetics. 1994. PMID: 7987401 Review. No abstract available.
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.
Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER. Lau WC, et al. Among authors: watkins pb. Circulation. 2004 Jan 20;109(2):166-71. doi: 10.1161/01.CIR.0000112378.09325.F9. Epub 2004 Jan 5. Circulation. 2004. PMID: 14707025 Clinical Trial.
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.
Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Lau WC, et al. Among authors: watkins pb. Circulation. 2003 Jan 7;107(1):32-7. doi: 10.1161/01.cir.0000047060.60595.cc. Circulation. 2003. PMID: 12515739 Clinical Trial.
Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Paine MF, et al. Among authors: watkins pb. Clin Pharmacol Ther. 2002 Nov;72(5):524-35. doi: 10.1067/mcp.2002.128387. Clin Pharmacol Ther. 2002. PMID: 12426516
Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.
Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Schmiedlin-Ren P, et al. Among authors: watkins pb. Mol Pharmacol. 1997 May;51(5):741-54. doi: 10.1124/mol.51.5.741. Mol Pharmacol. 1997. PMID: 9145912
Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease.
Fontana RJ, deVries TM, Woolf TF, Knapp MJ, Brown AS, Kaminsky LS, Tang BK, Foster NL, Brown RR, Watkins PB. Fontana RJ, et al. Among authors: watkins pb. Br J Clin Pharmacol. 1998 Sep;46(3):221-8. doi: 10.1046/j.1365-2125.1998.00776.x. Br J Clin Pharmacol. 1998. PMID: 9764962 Free PMC article. Clinical Trial.
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL. Cheng CL, et al. Among authors: watkins pb. Clin Pharmacol Ther. 1997 May;61(5):531-43. doi: 10.1016/S0009-9236(97)90133-8. Clin Pharmacol Ther. 1997. PMID: 9164415 Clinical Trial.
Genetic predisposition to drug-induced liver disease.
Fontana RJ, Watkins PB. Fontana RJ, et al. Among authors: watkins pb. Gastroenterol Clin North Am. 1995 Dec;24(4):811-38. Gastroenterol Clin North Am. 1995. PMID: 8749900 Review.
Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. A prospective study in renal transplant recipients.
Turgeon DK, Leichtman AB, Blake DS, Schmouder RL, Lown KS, Annesley TM, Watkins PB. Turgeon DK, et al. Among authors: watkins pb. Transplantation. 1994 Jun 27;57(12):1736-41. Transplantation. 1994. PMID: 8016878 Clinical Trial.
The erythromycin breath test predicts the clearance of midazolam.
Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, Watkins PB. Lown KS, et al. Among authors: watkins pb. Clin Pharmacol Ther. 1995 Jan;57(1):16-24. doi: 10.1016/0009-9236(95)90261-9. Clin Pharmacol Ther. 1995. PMID: 7828377
252 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback